Patent: 10,261,091
✉ Email this page to a colleague
Summary for Patent: 10,261,091
Title: | Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome |
Abstract: | Compositions and methods are provided herein for predicting therapeutic outcome by measuring patient response to cellular antigen specific active immunotherapy (CASAI) using predetermined biomarkers. |
Inventor(s): | GuhaThakurta; Debraj (Sammamish, WA), Trager; James (Seattle, WA), Sheikh; Nadeem (Seattle, WA) |
Assignee: | Dendreon Corporation (Seattle, WA) |
Application Number: | 14/479,084 |
Patent Claims: | see list of patent claims |
Details for Patent 10,261,091
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Dendreon Pharmaceuticals Llc | PROVENGE | sipuleucel-t | Injection | 125197 | 04/29/2010 | ⤷ Try a Trial | 2033-09-05 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |